Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Company Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Key Stats

• Today's Range: $187.24 to $193.74
• 50-Day Range: $163.32 to $195.98
• 52-Week Range: $111.09 to $199.99
• Volume: 383,694 shs
• Average Volume: 496,593 shs
• Market Capitalization: $11.74 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $242.93
• Consensus Rating: Buy

Ascendis Pharma A/S Stock Analysis - MarketRank™

Ascendis Pharma A/S scored higher than 65% of companies evaluated by MarketBeat, and ranked 311th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ascendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ascendis Pharma A/S has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ascendis Pharma A/S is -37.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ascendis Pharma A/S is -37.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.52% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascendis Pharma A/S does not currently pay a dividend.

Dividend Growth

Ascendis Pharma A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.52% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.84

News Sentiment

Ascendis Pharma A/S has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 33 news articles for Ascendis Pharma A/S this week, compared to 8 articles on an average week.

Search Interest

Only 9 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

2 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

ASND Stock Analysis - Frequently Asked Questions

How have ASND shares performed this year?

Ascendis Pharma A/S's stock was trading at $137.67 on January 1st, 2025. Since then, ASND stock has increased by 39.5% and is now trading at $192.04.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The biotechnology company had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million.
Read the conference call transcript.

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Top institutional shareholders of Ascendis Pharma A/S include Westfield Capital Management Co. LP (8.91%), Artisan Partners Limited Partnership (6.53%), Massachusetts Financial Services Co. MA (3.11%) and American Century Companies Inc. (0.87%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASND
• CIK: 1612042
• Web: www.ascendispharma.com
• Phone: (457) 022-2244
• Fax: 45-3694-4010
• Employees: 1,017
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ascendis Pharma A/S: $242.93
• High Price Target: $307.00
• Low Price Target: $153.00
• Potential Upside/Downside: +27.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$409.12 million
• Net Margins: -54.94%
• Pretax Margin: -53.33%
• Return on Equity: N/A
• Return on Assets: -24.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.02
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $393.54 million
• Price / Sales: 29.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.48) per share
• Price / Book: -54.91

Miscellaneous

• Outstanding Shares: 61,150,000
• Free Float: 36,691,000
• Market Cap: $11.68 billion
• Optionable: Optionable
• Beta: 0.41